Dhawan told CNBC-TV18, "In Ranbaxy Laboratories there has been a disaster for the investors over the last few weeks. One bad news comes and another one comes on straight after. I think shareholders obviously must be perplexed. I think the reality is that longer-term investors probably still wouldn't have exited they probably have held on. Some investors we knew applied for that open offer but that is a very small percentage of their stocks, which will be accepted."
He further added, "On current levels if you look at a price to earnings (PE) ratio, still not cheapest of stocks. It is sector which we never particularly liked because of all these news, which can come and have adverse impacts. The fact that the domestic Indian investors exited should hint investors currently what he feels and what he has thought of the company's future prospects. So investors if they were looking for fresh approach probably ignore it and if you have got it then probably just hold on, I don't see any more bad news that can really come in a short-term and it will be interesting to see how much institutional offloading there has been if any today."
Disclosure: It is safe to assume that analyst and his clients may have an investment interest in the above stock/sector.